GlaxoSmithKline receives antitrust penalty: the agreement to delay the entry of generic drugs is illegal
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-06
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AiolosBio: The Middleman with an Eye for Opportunity in the Pharmaceutical Industry?
-
Breakthrough Collaboration: Johnson Pharmaceuticals and GSK Join Forces to Advance ADC Therapy HS-20093
-
GlaxoSmithKline Acquires Exclusive Licensing Rights for Johnson Pharmaceuticals' Promising ADC Drug HS-20089: A Potential Breakthrough Therapy for Gynecologic Cancers
-
GlaxoSmithKline Pharmaceuticals Reports 11% Rise in Q1 Profit Driven by Strong Demand for Vaccines
-
3 billion, nearly 10 years, why GlaxoSmithKline again?
-
A large number of pharmaceutical companies are in trouble
-
GlaxoSmithKline HPV Vaccine Two-dose Schedule Approved in China
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
European EMA Removes About 100 Generic Drugs Involving Johnson & Johnson, Sandoz, Teva, etc.
-
BASF Raises API and Excipient Prices
Recommend Reading
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
IPEC Updates Excipient Qualification Guidance
-
West Asia Tensions Squeeze Pharma Raw Materials
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Etilen Vinil Acetato: Properties, Uses, and Applications
-
February Ammonium Sulfate Market Continues to Rise in China
-
BASF's Zhanjiang Integrated Site Reaches Major Milestone: Butyl Acrylate Production Commences Ahead of Schedule, Steam Cracker Completes Mechanical Completion
-
Short-term Costs and Demand Both Driving Melamine Prices to Stay Stable and Improve
-
Geno and Sojitz Collaborate to Accelerate the Commercialization of Nylon 6